The role of clusterin in Alzheimer's disease: Pathways, pathogenesis, and therapy

Molecular Neurobiology

Volumn 45, Issue 2, 2012, Pages 314-326

  Yu, Jin Tai ^a,b   Tan, Lan ^a,b  

^a QINGDAO UNIVERSITY   (China)

^b OCEAN UNIVERSITY OF CHINA   (China)

Author keywords

Alzheimer's disease; Amyloid ; Clusterin; Genetics; Pathogenesis; Therapy

Indexed keywords

AMYLOID BETA PROTEIN; CLUSTERIN; CLUSTERIN PEPTIDE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; APOPTOSIS; BEHAVIOR DISORDER; CELL CYCLE REGULATION; COGNITIVE DEFECT; DISEASE COURSE; EPIGENETICS; GENE EXPRESSION; GENETIC VARIABILITY; GENOME ANALYSIS; HUMAN; LIPID METABOLISM; NERVE CELL; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PATHOGENESIS; PROTEIN AGGREGATION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84862777328     PISSN: 08937648     EISSN: 15591182     Source Type: Journal    
DOI: 10.1007/s12035-012-8237-1     Document Type: Review

References (104)

1. Bertram L et al (2007) Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. Nat Genet 39:17-23
2. Thambisetty M et al (2010) Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease. Arch Gen Psychiatry 67:739-748
3. Schrijvers EM et al (2011) Plasma clusterin and the risk of Alzheimer disease. JAMA 305:1322-1326
4. Rizzi F et al (2009) Chapter 2: clusterin (CLU): from one gene and two transcripts to many proteins. Adv Cancer Res 104:9-23
5. de Silva HV et al (1990) Apolipoprotein J: structure and tissue distribution. Biochemistry 29:5380-5389
6. Jones SE, Jomary C (2002) Clusterin. Int J Biochem Cell Biol 34:427-431
7. Nuutinen T et al (2009) Clusterin: a forgotten player in Alzheimer's disease. Brain Res Rev 61:89-104
8. Argraves WS, Morales CR (2004) Immunolocalization of cubilin, megalin, apolipoprotein J, and apolipoprotein A-I in the uterus and oviduct. Mol Reprod Dev 69:419-427
9. Collard MW, Griswold MD (1987) Biosynthesis and molecular cloning of sulfated glycoprotein 2 secreted by rat Sertoli cells. Biochemistry 26:3297-3303
10. Butler AW et al (2009) Meta-analysis of linkage studies for Alzheimer's disease - a web resource. Neurobiol Aging 30:1037-1047
11. Harold D et al (2009) Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet 41:1088-1093
12. Lambert JC et al (2009) Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet 41:1094-1099
13. Seshadri S et al (2010) Genome-wide analysis of genetic loci associated with Alzheimer disease. JAMA 303:1832-1840
14. Naj AC et al (2011) Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet 43:436-441
15. Schjeide BM et al (2011) The role of clusterin, complement receptor 1, and phosphatidylinositol binding clathrin assembly protein in Alzheimer disease risk and cerebrospinal fluid biomarker levels. Arch Gen Psychiatry 68:207-213
16. Corneveaux JJ et al (2010) Association of CR1, CLU and PICALM with Alzheimer's disease in a cohort of clinically characterized and neuropathologically verified individuals. Hum Mol Genet 19:3295-3301
17. Lee JH et al (2009) Identification of novel loci for Alzheimer disease and replication of CLU, PICALM, and BIN1 in Caribbean Hispanic individuals. Arch Neurol 68:320-328
18. Carrasquillo MM et al (2010) Replication of CLU, CR1, and PICALM associations with Alzheimer disease. Arch Neurol 67:961-964
19. Kamboh MI et al (2010) Association of CLU and PICALM variants with Alzheimer's disease. Neurobiol Aging 33:518-521
20. Yu JT et al (2010) Implication of CLU gene polymorphisms in Chinese patients with Alzheimer's disease. Clin Chim Acta 411:1516-1519
21. Jun G et al (2010) Meta-analysis confirms CR1, CLU, and PICALM as Alzheimer disease risk loci and reveals interactions with APOE genotypes. Arch Neurol 67:1473-1484
22. Wijsman EM et al (2011) Genome-wide association of familial late-onset Alzheimer's disease replicates BIN1 and CLU and nominates CUGBP2 in interaction with APOE. PLoS Genet 7:e1001308
23. Guerreiro RJ et al (2010) Genetic variability in CLU and its association with Alzheimer's disease. PLoS One 5:e9510
24. Szymanski M et al (2011) Alzheimer's risk variants in the Clusterin gene are associated with alternative splicing. Transl Psychiatr 1:e18
25. Schürmann B et al (2011) Association of the Alzheimer's disease clusterin risk allele with plasma clusterin concentration. J Alzheimers Dis 25:421-424
26. Xing YY et al (2012) Blood clusterin levels, rs9331888 polymorphism, and the risk of Alzheimer's disease. J Alzheimers Dis. doi:10.3233/JAD-2011-111844
27. DeMattos RB et al (2004) ApoE and clusterin cooperatively suppress Abeta levels and deposition: evidence that ApoE regulates extracellular Abeta metabolism in vivo. Neuron 41:193-202
28. Thambisetty M et al (2010) Proteome-based plasma markers of brain amyloid-β deposition in non-demented older individuals. J Alzheimers Dis 22:1099-1109
29. Chouliaras L et al (2010) Epigenetic regulation in the pathophysiology of Alzheimer's disease. Prog Neurobiol 90:498-510
30. Loison F et al (2006) Up-regulation of the clusterin gene after proteotoxic stress: implication of HSF1-HSF2 heterocomplexes. Biochem J 395:223-231
31. Rauhala HE et al (2008) Clusterin is epigenetically regulated in prostate cancer. Int J Cancer 123:1601-1609
32. Nuutinen T et al (2005) Induction of clusterin/apoJ expression by histone deacetylase inhibitors in neural cells. Neurochem Int 47:528-538
33. Suuronen T et al (2007) Epigenetic regulation of clusterin/apolipoprotein J expression in retinal pigment epithelial cells. Biochem Biophys Res Commun 357:397-401
34. Hellebrekers et al (2007) Identification of epigenetically silenced genes in tumor endothelial cells. Cancer Res 67:4138-4148
35. Calvanese Vet al (2009) The role of epigenetics in aging and age-related diseases. Ageing Res Rev 8:268-276
36. Wang SC et al (2008) Age-specific epigenetic drift in late-onset Alzheimer's disease. PLoS One 3:e2698
37. Wu J et al (2008) The environment, epigenetics and amyloidogenesis. J Mol Neurosci 34:1-7
38. Chuang DM et al (2009) Multiple roles of HDAC inhibition in neurodegenerative conditions. Trends Neurosci 32:591-601
39. Francis YI et al (2009) Dysregulation of histone acetylation in the APP/PS1 mouse model of Alzheimer's disease. J Alzheimers Dis 18:131-139
40. Marks PA, Xu WS (2009) Histone deacetylase inhibitors: potential in cancer therapy. J Cell Biochem 107:600-608
41. May PC et al (1990) Dynamics of gene expression for a hippocampal glycoprotein elevated in Alzheimer's disease and in response to experimental lesions in rat. Neuron 5:831-839
42. Lidström AM et al (1998) Clusterin (apolipoprotein J) protein levels are increased in hippocampus and in frontal cortex in Alzheimer's disease. Exp Neurol 154:511-521
43. Giannakopoulos P et al (1998) Possible neuroprotective role of clusterin in Alzheimer's disease: a quantitative immunocytochemical study. Acta Neuropathol 95:387-394
44. Bertrand P et al (1995) Association of apolipoprotein E genotype with brain levels of apolipoprotein E and apolipoprotein J (clusterin) in Alzheimer disease. Brain Res Mol Brain Res 33:174-178
45. Harr SD et al (1996) Brain expression of apolipoproteins E, J, and A-I in Alzheimer's disease. J Neurochem 66:2429-2435
46. Suzuki T et al (2002) Predominant apolipoprotein J exists as lipid-poor mixtures in cerebrospinal fluid. Ann Clin Lab Sci 32:369-376
47. Nilselid AM et al (2006) Clusterin in cerebrospinal fluid: analysis of carbohydrates and quantification of native and glycosylated forms. Neurochem Int 48:718-728
48. Ghiso J et al (1993) The cerebrospinal-fluid soluble form of Alzheimer's amyloid beta is complexed to SP-40,40 (apolipoprotein J), an inhibitor of the complement membrane-attack complex. Biochem J 293:27-30
49. Sihlbom C et al (2008) Structural and quantitative comparison of cerebrospinal fluid glycoproteins in Alzheimer's disease patients and healthy individuals. Neurochem Res 33:1332-1340
50. Thambisetty M et al (2012) Plasma clusterin concentration is associated with longitudinal brain atrophy in mild cognitive impairment. NeuroImage 59:212-217
51. IJsselstijn L et al (2011) Serum clusterin levels are not increased in presymptomatic Alzheimer's disease. J Proteome Res 10:2006-2010
52. Trougakos IP, Gonos ES (2002) Clusterin/apolipoprotein J in human aging and cancer. Int J Biochem Cell Biol 34:1430-1448
53. Matsubara E et al (1996) Apolipoprotein J and Alzheimer's amyloid beta solubility. Biochem J 316:671-679
54. Yerbury JJ et al (2007) The extracellular chaperone clusterin influences amyloid formation and toxicity by interacting with prefibrillar structures. FASEB J 21:2312-2322
55. Oda T et al (1995) Clusterin (apoJ) alters the aggregation of amyloid beta-peptide (A beta 1-42) and forms slowly sedimenting A beta complexes that cause oxidative stress. Exp Neurol 136:22-31
56. Lambert MP et al (1998) Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci U S A 95:6448-6453
57. Narayan P et al (2011) The extracellular chaperone clusterin sequesters oligomeric forms of the amyloid-β(1-40) peptide. Nat Struct Mol Biol 19:79-83
58. DeMattos RB et al (2002) Clusterin promotes amyloid plaque formation and is critical for neuritic toxicity in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 99:10843-10848
59. Wang YJ et al (2006) Clearance of amyloid-beta in Alzheimer's disease: progress, problems and perspectives. Drug Discov Today 11:931-938
60. Cirrito JR et al (2003) In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-beta metabolism and half-life. J Neurosci 23:8844-8853
61. Bateman RJ et al (2006) Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo. Nat Med 12:856-861
62. Bu G (2009) Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy. Nat Rev Neurosci 10:333-344
63. Bell RD et al (2007) Transport pathways for clearance of human Alzheimer's amyloid beta-peptide and apolipoproteins E and J in the mouse central nervous system. J Cereb Blood Flow Metab 27:909-918
64. Pluta R (2007) Role of ischemic blood-brain barrier on amyloid plaques development in Alzheimer's disease brain. Curr Neurovasc Res 4:121-129
65. Zlokovic BV et al (1996) Glycoprotein 330/megalin: probable role in receptor-mediated transport of apolipoprotein J alone and in a complex with Alzheimer disease amyloid beta at the blood-brain and blood-cerebrospinal fluid barriers. Proc Natl Acad Sci USA 93:4229-4234
66. Calero M et al (2000) Apolipoprotein J (clusterin) and Alzheimer's disease. Microsc Res Tech 50:305-315
67. Hammad SM et al (1997) Interaction of apolipoprotein J-amyloid beta-peptide complex with low density lipoprotein receptor-related protein-2/megalin. A mechanism to prevent pathological accumulation of amyloid beta-peptide. J Biol Chem 272:18644-18649
68. LaDu MJ et al (2000) Apolipoprotein E receptors mediate the effects of beta-amyloid on astrocyte cultures. J Biol Chem 275:33974-33980
69. Nuutinen T et al (2007) Amyloid-beta 1-42 induced endocytosis and clusterin/apoJ protein accumulation in cultured human astrocytes. Neurochem Int 50:540-547
70. Calero M et al (1999) Functional and structural properties of lipid-associated apolipoprotein J (clusterin). Biochem J 344:375-383
71. Ishikawa Yet al (1998) Distribution and synthesis of apolipoprotein J in the atherosclerotic aorta. Arterioscler Thromb Vasc Biol 18:665-672
72. Gelissen IC et al (1998) Apolipoprotein J (clusterin) induces cholesterol export from macrophage-foam cells: a potential anti-atherogenic function? Biochem J 331:231-237
73. Miwa Yet al (2005) Insertion/deletion polymorphism in clusterin gene influences serum lipid levels and carotid intima-media thickness in hypertensive Japanese females. Biochem Biophys Res Commun 331:1587-1593
74. Martins IJ et al (2009) Cholesterol metabolism and transport in the pathogenesis of Alzheimer's disease. J Neurochem 111:1275-1308
75. Salminen A et al (2009) Inflammation in Alzheimer's disease: amyloid-beta oligomers trigger innate immunity defence via pattern recognition receptors. Prog Neurobiol 87:181-194
76. Ferretti MT et al (2011) Intracellular Aβ-oligomers and early inflammation in a model of Alzheimer's disease. Neurobiol Aging. doi:10.1016/j.neurobiolaging.2011.01.007
77. in t' Veld BA et al (2001) Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. N Engl J Med 345:1515-1521
78. Varvel NH et al (2009) NSAIDs prevent, but do not reverse, neuronal cell cycle reentry in a mouse model of Alzheimer disease. J Clin Invest 119:3692-3702
79. Mrak RE, Griffin WS (2005) Glia and their cytokines in progression of neurodegeneration. Neurobiol Aging 26:349-354
80. Xie Z et al (2005) Apolipoprotein J (clusterin) activates rodent microglia in vivo and in vitro. J Neurochem 93:1038-1046
81. Falgarone G, Chiocchia G (2009) Chapter 8: clusterin: a multifacet protein at the crossroad of inflammation and autoimmunity. Adv Cancer Res 104:139-170
82. Urbich C et al (2000) Laminar shear stress upregulates the complement-inhibitory protein clusterin: a novel potent defense mechanism against complement-induced endothelial cell activation. Circulation 101:352-355
83. Kirszbaum L et al (1992) SP-40,40, a protein involved in the control of the complement pathway, possesses a unique array of disulphide bridges. FEBS Lett 297:70-76
84. Essabbani A et al (2010) Identification of clusterin domain involved in NF-kappaB pathway regulation. J Biol Chem 285:4273-4277
85. Takase O et al (2008) Inhibition of NF-kappaB-dependent Bcl-xL expression by clusterin promotes albumin-induced tubular cell apoptosis. Kidney 73:567-577
86. Frautschy SA et al (2005) Apolipoprotein J (clusterin) activates rodent microglia in vivo and in vitro. J Neurochem 93:1038-1046
87. Jin G, Howe PH (1997) Regulation of clusterin gene expression by transforming growth factor β. J Biol Chem 272:26620-26626
88. Santilli G et al (2003) Essential requirement of apolipoprotein J (clusterin) signaling for IkappaB expression and regulation of NF-kappaB activity. J Biol Chem 278:38214-38219
89. Lee KB et al (2008) Clusterin, a novel modulator of TGF-beta signaling, is involved in Smad2/3 stability. Biochem Biophys Res Commun 366:905-909
90. Morgan TE et al (1995) Clusterin expression by astrocytes is influenced by transforming growth factor beta 1 and heterotypic cell interactions. J Neuroimmunol 58:101-110
91. Shannan B et al (2006) Clusterin and DNA repair: a new function in cancer for a key player in apoptosis and cell cycle control. J Mol Histol 37:183-188
92. Moretti RM et al (2007) Clusterin isoforms differentially affect growth and motility of prostate cells: possible implications in prostate tumorigenesis. Cancer Res 67:10325-10333
93. Pucci S et al (2004) Modulation of different clusterin isoforms in human colon tumorigenesis. Oncogene 23:2298-2304
94. Bettuzzi S et al (2002) Clusterin (SGP-2) transient overexpression decreases proliferation rate of SV40-immortalized human prostate epithelial cells by slowing down cell cycle progression. Oncogene 21:4328-4334
95. Zellweger T et al (2003) Overexpression of the cytoprotective protein clusterin decreases radiosensitivity in the human LNCaP prostate tumour model. BJU Int 92:463-469
96. Arendt T, Bruckner MK (2007) Linking cell-cycle dysfunction in Alzheimer's disease to a failure of synaptic plasticity. Biochim Biophys Acta 1772:413-421
97. Wu ZC et al (2012) CLU in Alzheimer's disease. Adv Clin Chem 56:155-165
98. Braskie MN et al (2011) Common Alzheimer's disease risk variant within the CLU gene affects white matter microstructure in young adults. J Neurosci 31:6764-6770
99. Lancaster TM et al (2011) Neural hyperactivation in carriers of the Alzheimer's risk variant on the clusterin gene. Eur Neuropsychopharmacol 21:880-884
100. Mengel-From J et al (2011) Genetic variations in the CLU and PICALM genes are associated with cognitive function in the oldest old. Neurobiol Aging 32:554.e7-554.e11
101. Dati G et al (2007) Beneficial effects of r-h-CLU on disease severity in different animal models of peripheral neuropathies. J Neuroimmunol 190:8-17
102. Navab M et al (2005) An oral apoJ peptide renders HDL anti-inflammatory in mice and monkeys and dramatically reduces atherosclerosis in apolipoprotein E-null mice. Arterioscler Thromb Vasc Biol 25:1932-1937
103. Sleegers K et al (2010) The pursuit of susceptibility genes for Alzheimer's disease: progress and prospects. Trends Genet 26:84-93
104. Nuutinen Tet al (2010)Valproic acid stimulates clusterin expression in human astrocytes: implications for Alzheimer's disease. Neurosci Lett 475:64-68